Sanofi clears key multiple sclerosis milestone, shares underpinned by solid pipeline outlook
Published on 06/25/2026 at 14:21 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWS
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-25, 14:20.
Sanofi (FR0000120578) this week reported fresh regulatory progress in neurology and immunology. The Nasdaq-listed group obtained European Commission approval for its multiple sclerosis therapy Cenrifki and a separate Japanese green light for immune disorder drug Wayrilz, according to recent company disclosures and market reports.
What the new approvals cover
The European Commission has cleared Cenrifki (tolebrutinib) as the first disability-focused treatment for non-relapsing secondary progressive multiple sclerosis, giving Sanofi a differentiated entrant in a competitive MS field that includes Novartis and Roche, as summarized by MarketScreener from company communications.MarketScreener news overview on Sanofi
In Japan, the Ministry of Health, Labour and Welfare has approved Wayrilz (rilzabrutinib) for the treatment of immune thrombocytopenia, adding another BTK inhibitor-based option in a niche autoimmune indication where competition from other large pharma players remains limited, according to the same news flow.MarketScreener compilation on Wayrilz approval
Pipeline and earnings backdrop
Beyond these approvals, recent commentary from industry media highlights that Sanofi’s first quarter 2026 revenues grew by roughly 13.6 percent at constant exchange rates to just over €10.5 billion, driven primarily by immunology drug Dupixent and newer launches, underscoring a pipeline that is already contributing to the top line.Pharmaphorum report on Sanofi’s Q1 2026 performance
The same report notes that newer products including haemophilia A therapy Altuviiio and type 1 diabetes treatment Tzield generated about €1.1 billion in quarterly sales, rising close to 50 percent year-on-year, supporting management’s guidance for high single-digit sales growth in 2026 at constant exchange rates.Pharmaphorum guidance commentary
All news and analysis on the Sanofi shares
Further company releases, analyst estimates and regulatory headlines on Sanofi are collected in the dedicated topic section and on the group’s investor relations pages.
The therapies behind the stock
Sanofi’s prescription portfolio centers on specialty care, vaccines and general medicines, with key growth drivers in immunology such as Dupixent for atopic dermatitis and asthma, and newer entries including Cenrifki for multiple sclerosis and Wayrilz for immune thrombocytopenia alongside established vaccines and diabetes products.Sanofi investor information on portfolio
Where the shares trade today
Sanofi shares (FR0000120578) most actively trade in the United States on Nasdaq under the ticker SNY, where they closed at 41.33 USD on 2026-06-24 at 22:00 CET, implying a market capitalization around 99 to 101 billion USD.MarketScreener price and market cap data
Key data on the Sanofi shares
- Company: Sanofi S.A.
- ISIN: FR0000120578
- WKN: 920657
- Ticker: SNY
- Trading venue: Nasdaq
- Price (as of 2026-06-24, 22:00): 41.33 USD
- Market cap: around 99-101 billion USD (as of 2026-06-24)
- Sector / industry: Pharmaceuticals / Biotechnology
- Index membership: S&P 500 (via U.S.-listed ADR peer group exposure) and Euro Stoxx healthcare benchmarks as tracked by major index providers
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, an offer, or a recommendation to buy or sell any securities. Investors should conduct their own research and consider their individual financial situation before making investment decisions.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
